Toxicologists need more information than is usually available in the early stages of development of a drug in order to choose proper dose levels for testing in the bioassays. The approach most likely to result in successful bioassays involves an early multidisciplinary effort in which there is pharmacokinetic characterization of the test material in both rats and mice. Preliminary 3 month studies are desirable. Periodic sampling of plasma is essential to detect possible non-linear kinetics (as in the example we report herein) reflected as accumulation of the test material or metabolites. This is true regardless of the test substance. However, if one tests prodrugs it may be particularly helpful to know if chemical or enzymatic conversion of the prodrug is linear and if there is reversion to prodrug or other abberant metabolism. Failure to rule out these possibilities could result in subsequent clinically irrelevant organ damage or could compromise longevity or the interpretation of results in lifetime studies. Pharmacokinetic considerations are as valid as the more traditional biologic or morphologic end points used to estimate maximum tolerated or no-effect dose levels.
INTRODUCTION
The purpose of this paper is to provide data which illustrate the importance of toxicokinetics to the selection of dose levels for carcinogenicity bioassays in mice and rats. In our laboratory we routinely perform preliminary dose-range finding studies to set dosing regimens for carcinogencity bioassays. These are usually of 3 months duration and include periodic plasma level determinations.
In the recent conduct of such studies with a prodrug (being developed to enhance bioavailability of a drug product of therapeutic interest) essential data was obtained which underscores the vital role of toxicokinetics in dose selection.
METHODS
We performed 3 month preliminary studies of the prodrug at two dose levels in both sexes * Presented at the Second International Symposium of the Society of Toxicologic Pathlogists, Session I: "Protocols Past and Present", hlay 9-11, 1983, Arlington, Virginia.
This Symposium section will be continued in Volume 11. Number 2.1983. of mice and rats purchased from Charles River Breeding Laboratories. The test material (prodrug) was suspended in 0.25% sterile agar and given by gavage once each day for 3 months. The dose levels tested in mice were 0,100 and 200 mg/kg/day and in rats 0,200 and 400 mg/kg/day. Single dose pharmacokinetic studies had established that the test material (prodrug) was absorbed much better in mice than in rats dosed by gastric intubation. The essentials of the study design were that the animals were weighed each week and that there were periodic samplings for hematologic and serum chemical tests as well as routine necropsy and evaluation of a wide variety of tissues by light microscopy. We determined the concentration of the prodrug and its conversion product of therapeutic interest (drug) in plasma taken from 3 mice and rats/sex/group on dose days 1, 30 and 87. Analysis was by radioimmunoassay.
RESULTS
At the end of the 3 month treatment period there were small but treatment-related de-56 SZCZECH AND TUCKER TOXICOLOGIC PATHOLOGY creases in body weights for all animals except female rats given 200 mg/kg/day of the prodrug ( Table 1) . The decreased body weights were no more than 6% lower than the corresponding control values. This would not qualify as being a sign that "maximum tolerated doses" were tested according to the practice of seeking a 10% decrease in body weight. However, increased values for serum creatinine suggested that the kidney was a target organ in both male and female mice treated (at both the 100 and 200 mg/kg/day dose levels) for 3 months. But there were no microscopic renal lesions in mice nor was there a sign of increased values for serum creatinine in the rats. Although hematologic and serum chemical tests were normal for the rats, organ weight data and microscopy revealed adverse (but reversible) effects on the testicle.
There was evidence of a progressive increase in mean values for plasma concentrations of both the prodrug (test substance) and the drug in both the mice and rats. The data suggested nonlinear pharmacokinetic behavior of the prodrug that would have been impossible to detect with single dose or shortterm exposure. The data displayed in Table  2 (mice) and Table 3 (rats) indicates a similar effect in both species.
The values in the tables are mean values for 3 animals of each sex, the only important sex difference being in high dose rats on day 87 as delineated in the footnotes to Table 3 . Some important differences need to be emphasized. On dose day 1 rats given 400 mg/ kg of the prodrug had plasma levels of both the prodrug and its product of conversion (drug) that were considerably larger than twice the values found at the 200 mg/kg dose level. This could have been a very early sign that larger doses might not be properly eliminated. The results further demonstrate that, even at the lower dose levels and in both species, plasma levels of both the prodrug and drug remained higher for longer periods of time after 87 days of exposure than they did after 1 or 30 days of exposure. Finally, there was one important sex-specific difference. Plasma levels of both the prodrug and drug were many multiples larger in high dose male rats than they were in high dose female rats sampled 6 hours postdose after 87 days of exposure. This difference was not apparent at the lower dose (200 mg/kg/day) or at the earlier sampling times (dose days 1 and 30). Furthermore, this difference was not apparent in rats in the same treatment group (400 mg/kg/day) sampled 1 hour postdose after 87 days of exposure.
DlscusSloN
Our results provide another example of the necessity for a substantial and timely multidisciplinary approach to the selection of appropriate dose levels for testing in lifetime studies. We used our preliminary studies to select dose levels of 25,50 and 100 mg/kg for * values are means for 3 males and 3 females sampled 0.5 hours postdose. Analyses were by radioimmunoassay.
** values are means for 3 males and 3 females sampled 4 hours postdose.
the rat bioassay and 25, 50 and 75 mg/kg for the mouse bioassay, doses which avoided a non-linear response as determined by the periodic analysis of plasma for drug and prodrug content.
Our approach is not original. The considerations are essentially the same for a prodrug as for any other test substance. Several years ago Gehring and Blau (1) noted that many excretory processes are saturable and Gehring et al. (2) provided evidence that high doses may lead to disproportionate increases in the toxicity or carcinogencity of several chemicals. Smyth and Hottendorf (3) also recommended a similar approach in a paper published in 1980. The end product of this additional effort may be bioassay results that are as relevant to the process of risk assessment as current knowledge will permit. ous consultations during the course of these studies. Mr. Steve Good and Ms. D. Page also in the Department of Experimental Therapy, performed the analyses for drug plasma levels.
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DISCUSSION OF THE PAPER DR. SZCZECH: I understand your concern; Dr. Vera Glocklin. It's really, in the end, a value judgment. The comment was that the abuse potential of a material can be quite different from the recommended use, and by implication, this would be a reason to test as high a dose as one could possibly test. I couldn't agree more with that assessment. I don't think or at least I hope that I did not suggest that we should keep doses low intentionally so that nothing happens. Rather, I intended to suggest that we need a variety of information to set our dose levels, and when we have that information, we shouldn't be afraid to use it and to use it reasonably.
DR. PAYNE: Almost every speaker has talked about the need for pharmacokinetics, drug metabolism. We're a group of pathologists saying what some other discipline should do. My limited experience is that I do not have any control over that, and I'm faced with the situation of assessing for carcinogenicity, in fact without those nice data most of the time. My general impression is that that discipline does exist and that discipline can do that job in general; but it just often doesn't occur. I think I have faced one situation at least where there has been some kind of an end-run around that kind of a need and that is to do what has been referred to as a dose range and sighting study. Many of you have ridiculed this concept of mine before, and I will throw it up for ridicule again. When you first start off a dose range study, before starting a sub-acute, you set up a group of animals and dose them as high as you can, get deaths and follow a complete time/dose response relationship and just keep that experiment going. Then, when you get ready to do a cancer study, you have what is really the best dose range for a cancer study, and that's animals that have been dosed for two years. That's really the only good dose range for a two year cancer studya two year study. DR. SZCZECH: I agree with that as well.
DR. HESS: I have a very simple question -
how do you define a no observable-effect level"? DR. SZCZECH: This is one of the things that I think I get paid for. Another, and perhaps related reason, is to sort out artifacts. As we're all aware, artifacts can confound a variety of types of toxicology studies. The an-swer (it may not be satisfactory to you) is that it is an individual assessment on the part of the group working with the material, projecting potential adverse effects from all of the i n f o r~a t i o n available, be it a change in red blood cell count, be it an effect on the pancreas. The key in identifying the top dose or the effect dose is (as far as it relates to dose level selection) that it is that dose that can be predicted to either not affect natural life span or to cause a certain effect when given for the lifetime of rodents. Sometimes there's luck involved. Some groups and some people are better predictors than others. Sometimes, despite one's best efforts, the prediction falls far short. We're dealing in a world that requires the use of judgment and reason and we do the best that we can. That's all I can say.
DR. HESS: I'm grateful for this comment because as it is a statistical matter, you may be far off the actual goal.
DR. SZCZECH: My response to that is -I once heard the comment that "if you need statistics to evaluate a toxicity study, you probably need to re-design the study." DR. BARTHEL: George, I also wanted to ask as wellthis may be somewhat of a blasphemous questionhow well does "blind" histopathologic evaluation apply to these types of drugs? DR. SZCZECH: If you've just asked what my feeling is on "blind" reading of slides, it is that if you have a known quantity, if you know at what level the individuals doing the work are looking at the slides, it is a gross waste of expensive time to start out with "blind" reading. I think when you have all the information you can have and you suspect certain things, you then are in a mode where you can go back to "blind" reading. Anytime there's a need for this, I think it's absolu~ely essential. It is something that we do in our shop on a daily basis; that is when I suspect a specific morphologic effect at a particular dose level or with a particular compound, I always "blind" to the extent that I was almost going to write a vice-president of Three M to make little tags that we can stick on top of slides like those little yellow self adhering sheets that they've been fairly successful with. You can stick it on and nobody knows what's there, and then'you can peel it off without damaging, for GLP purposes, anything that might be on the slide. It's essential and it's critical.
